Mankind Pharma (MANKIND) | Stock Overview & Key Data
Mankind Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹3,054.80 on December 23, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mankind Pharma
MANKIND
|
946.57B Large-cap | 0.97% | -4.90% | 13.63% | 11.17% | 9.96% | -0.01% | 46.65% | 70.76% | 70.76% | 70.76% | 70.76% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Torrent
TORNTPHARM
|
1.39T Large-cap | 2.12% | 2.23% | 5.56% | 19.07% | 17.04% | 40.54% | 146.00% | 215.51% | 578.42% | 2,737.14% | 10,046.95% |
|
Dr. Reddy's
DRREDDY
|
1.10T Large-cap | 0.31% | -4.28% | 0.20% | -0.09% | 2.08% | -6.39% | 29.74% | 20.69% | 112.36% | 310.53% | 902.28% |
|
Lupin
LUPIN
|
1.07T Large-cap | 0.83% | -0.14% | -0.76% | 8.63% | 8.10% | 14.69% | 176.15% | 98.45% | 56.65% | 418.49% | 2,332.69% |
Ownership & Short Interest
Calculate Your Mankind Pharma Investment Returns
Long-Term Investment Performance Analysis
Mankind Pharma stock price in May 2023 was ₹1,394.45, A ₹1,000.00 lump sum investment in Mankind Pharma made 3 years ago would be worth approximately ₹1,706.98 today, representing a solid return of 70.70%. This translates to an annualized return (CAGR) of 18.80%.
3 Years 1 Month Investment Scenario (May 2023 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is MANKIND's 52-week high and low?
- In the last 52 weeks, Mankind Pharma reached a high of ₹2,716.50 (on July 15, 2025) and a low of ₹1,909.70 (on March 23, 2026).
- What is the market cap and P/E ratio for MANKIND?
- Curious about Mankind Pharma's size and valuation? Its market capitalization stands at 946.57B. When it comes to valuation, the P/E ratio (trailing twelve months) is 53.43, and the forward P/E (looking ahead) is 38.66.
- Does MANKIND pay dividends? If so, what's the yield?
- Yes, Mankind Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.04%, and the company has paid an average of ₹0.33 per share annually over the past 3 years.
- Who are Mankind Pharma's main competitors or similar companies to consider before investing?
When looking at Mankind Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Torrent
TORNTPHARM1.39T Healthcare Drug Manufacturers - Specialty & Generic 40.54% 146.00% Dr. Reddy's
DRREDDY1.10T Healthcare Drug Manufacturers - Specialty & Generic -6.39% 29.74% Lupin
LUPIN1.07T Healthcare Drug Manufacturers - Specialty & Generic 14.69% 176.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Mankind Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Mankind Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.67%, the Debt to Equity ratio from the most recent quarter is 53.89, and its Gross Profit Margin stands at 72.58%.
- What is the recent revenue and earnings growth for MANKIND?
- Looking at Mankind Pharma's growth, its revenue over the trailing twelve months (TTM) was INR139B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.40%, and quarterly earnings saw a YoY growth of 7.50%.
- How much of MANKIND stock is held by insiders and institutions?
- Wondering who owns Mankind Pharma stock? Company insiders (like executives and directors) hold about 75.27% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 17.86%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.